UK markets closed

BNTX Jan 2025 230.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.26000.0000 (0.00%)
As of 03:36PM EDT. Market open.
Full screen
Previous close0.2600
Open0.2600
Bid0.0500
Ask0.7500
Strike230.00
Expiry date2025-01-17
Day's range0.2600 - 0.2600
Contract rangeN/A
Volume1
Open interest90
  • Reuters

    UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

  • Reuters

    GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    (Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

  • Reuters

    Pfizer vs Moderna battle over COVID vaccine patents begins in UK

    Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.